Literature DB >> 8383102

In-vitro activity of azithromycin on Chlamydia trachomatis infected, polarized human endometrial epithelial cells.

P B Wyrick1, C H Davis, S T Knight, J Choong.   

Abstract

The in-vitro activity of azithromycin on Chlamydia trachomatis infected human endometrial epithelial cells, both primary and transformed cells growing in a polarized and non-polarized orientation, was analyzed. Addition of azithromycin two hours after adsorption inoculation with continued exposure until 72 h gave an MIC90 and MBC90 of 0.063 and 0.5 mg/L, respectively. In addition, the MBC results were more pronounced in infected cells growing in a polarized orientation. Numerous small fluorescent 'spots' (presumed small abnormal inclusions) were visible in the infected cells exposed to MIC concentrations of azithromycin. Immuno-transmission electron microscopy examination revealed intracellular inclusions filled with chlamydial envelope ghosts. Since standard diagnostic antigen detection methods use anti-envelope antibodies, the aberrant envelope-filled inclusions might be interpreted as viable inclusions by fluorescent microscopy and result in high false positive readings. To simulate treatment of an infected patient, azithromycin was added at 18 h to infected cells containing many reticulate bodies and exposure continued for 54 h after which killing of chlamydiae was seen. The use of polarized human cells may offer a more relevant in-vitro model system for examining the efficacy of antimicrobial action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383102     DOI: 10.1093/jac/31.1.139

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Chlamydia pneumoniae infection in polarized epithelial cell lines.

Authors:  Liisa Törmäkangas; Eveliina Markkula; Kari Lounatmaa; Mirja Puolakkainen
Journal:  Infect Immun       Date:  2010-03-29       Impact factor: 3.441

Review 2.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

3.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.

Authors:  R J Suchland; W M Geisler; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  The chlamydial inclusion preferentially intercepts basolaterally directed sphingomyelin-containing exocytic vacuoles.

Authors:  Elizabeth R Moore; Elizabeth R Fischer; David J Mead; Ted Hackstadt
Journal:  Traffic       Date:  2008-10-08       Impact factor: 6.215

6.  Bioequivalence of Two Formulations of a Single Oral Dose of 500-mg Azithromycin Granules: A Randomized, Open-Label, Two-Period Crossover Study in Healthy Han Chinese Volunteers.

Authors:  Jing Ren; Xue-Hua Jiang; Kejia Li; Chuanchuan Zhang; Chenrui Li; Ling Wang
Journal:  Curr Ther Res Clin Exp       Date:  2007-09

7.  The Effect of Intravitreal Azithromycin on the Albino Newborn Rabbit Retina.

Authors:  Duygu Cam; Ali Osman Saatci; Serap Cilaker Micili; Bekir Ugur Ergur; Revan Yildirim Karabag; Ismet Durak; Ayse Tulin Berk
Journal:  Open Ophthalmol J       Date:  2016-02-04

8.  Stromal Fibroblasts Drive Host Inflammatory Responses That Are Dependent on Chlamydia trachomatis Strain Type and Likely Influence Disease Outcomes.

Authors:  Amber Leah Jolly; Sameeha Rau; Anmol K Chadha; Ekhlas Ahmed Abdulraheem; Deborah Dean
Journal:  mBio       Date:  2019-03-19       Impact factor: 7.867

9.  A European perspective on topical ophthalmic antibiotics: current and evolving options.

Authors:  D Bremond-Gignac; F Chiambaretta; S Milazzo
Journal:  Ophthalmol Eye Dis       Date:  2011-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.